Medical experts rename PCOS to PMOS to reflect metabolic impact

Polycystic ovarian syndrome (PCOS) is being renamed to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect the condition as a multisystem disorder rather than an isolated ovarian issue. Medical experts note that the previous terminology may have delayed diagnoses by focusing too narrowly on ovarian cysts.

PMOS is recognized as a complex endocrine and metabolic condition driven largely by insulin resistance. It affects approximately one in eight women and can impact blood sugar regulation, mood, energy levels, and long-term heart health. Symptoms often include irregular menstrual cycles, acne, unwanted facial hair, and difficulty managing weight.

Because the condition involves hormonal and metabolic changes, women with PMOS face increased risks for type 2 diabetes, high blood pressure, and fatty liver disease. A global coalition of health leaders is calling for urgent research into PMOS subtypes to improve medical care and address the projected surge in prevalence among adolescents and young women.